ASSET OVERVIEW
A closer look at the opportunity.
Best-in-Class Opportunity
EGFR widely expressed in NSCLC and multiple solid tumors (EGFRwt, EGFRmut, ESCC, NPC, breast, SCLC).
Differentiated Design
Optimized DAR4 ADC with potent topoisomerase I inhibitor payload; favorable PK and therapeutic index.
Favorable Safety Profile
No ≥G3 ILD events; lower stomatitis, hematologic AEs vs competitor ADCs (Dato-Dxd, BL-B01D1).
Next-Gen Clinical Profile
Superior efficacy vs other EGFR ADCs; ORR >55% in EGFRwt NSCLC with 100% DCR; durable responses across tumors.
Regulatory Momentum
3 FDA Fast Track & 1 Breakthrough (CDE) designation; FDA-endorsed accelerated approval in NSCLC (2L EGFRwt, 3L EGFRmut).
Promising Clinical Development
Two pivotal global MRCTs starting Q4 2025; >1000 patients enrolled; launch expected 2027 (China) / 2028 (US/EU).
Source: existing JEA asset materials. These descriptions include historical development plans and sponsor-reported data; contact JEA for current status and supporting materials.
← Back to all opportunities